REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · IEX Real-Time Price · USD
12.58
-0.27 (-2.10%)
At close: Jul 19, 2024, 4:00 PM
12.63
+0.05 (0.40%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $86.73M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $15.62M. In the year 2023, REGENXBIO had annual revenue of $90.24M.
Revenue (ttm)
$86.73M
Revenue Growth
-20.90%
P/S Ratio
7.14
Revenue / Employee
$252,110
Employees
344
Market Cap
619.64M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
Dec 31, 2018 | 218.51M | 208.11M | 2,002.42% |
Dec 31, 2017 | 10.39M | 5.80M | 126.48% |
Dec 31, 2016 | 4.59M | -3.00M | -39.52% |
Dec 31, 2015 | 7.59M | 1.47M | 23.99% |
Dec 31, 2014 | 6.12M | 33.00K | 0.54% |
Dec 31, 2013 | 6.09M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRGNX News
- 4 weeks ago - REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients - PRNewsWire
- 4 weeks ago - REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II - PRNewsWire
- 5 weeks ago - REGENXBIO Announces Leadership Transition - PRNewsWire
- 6 weeks ago - REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - PRNewsWire
- 2 months ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 2 months ago - REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire
- 3 months ago - REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit - PRNewsWire